دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Table of Contents
doi : 10.1016/S0923-7534(22)04712-3
Volume 33, Issue 12, December 2022, Pages i-ii
Precision oncology for biliary tract tumors: it’s written in blood!
M. A. Gouda 1 & V. Subbiah
doi : 10.1016/j.annonc.2022.09.157
Volume 33, Issue 12, December 2022, Pages 1209-1211
The end of the second step of the World Health Organization analgesic ladder?
P. S. Bramati & E. Bruera*
doi : 10.1016/j.annonc.2022.08.085
Volume 33, Issue 12, December 2022, Pages 1212-1213
At the crossroad between checkpoint blockade and big data analyses: identification of novel biomarkers and potential targets
A. Jurj 1,2 , D. Qian 3 , G. A. Calin 1,4 * & K. Litchfield
doi : 10.1016/j.annonc.2022.10.507
Volume 33, Issue 12, December 2022, Pages 1214-1216
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
J. Haanen 1y, M. Obeid 2,3,4y, L. Spain 5,6,7 , F. Carbonnel 8,9 , Y. Wang 10 , C. Robert 11,12 , A. R. Lyon 13,14 , W. Wick 15,16 , M. Kostine 17 , S. Peters4 , K. Jordan18,19 & J. Larkin 20 , on behalf of the ESMO Guidelines Committee
doi : 10.1016/j.annonc.2022.10.001
Volume 33, Issue 12, December 2022, Pages 1217-1238
Somatic variation in normal tissues: friend or foe of cancer early detection?
A. Acha-Sagredo 1,2y, P. Ganguli 1,2y & F. D. Ciccarelli
doi : 10.1016/j.annonc.2022.09.156
Volume 33, Issue 12, December 2022, Pages 1239-1249
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
C. E. Geyer, Jr.1,2 , J. E. Garber 3 , R. D. Gelber 3,4,5 , G. Yothers1,6 , M. Taboada 7 , L. Ross8 , P. Rastogi 1,2 , K. Cui 9 , A. Arahmani 10 , G. Aktan11 , A. C. Armstrong12 , M. Arnedos 13,14 , J. Balmaña15 , J. Bergh 16 , J. Bliss 17 , S. Delaloge18 , S. M. Domchek19 , A. Eisen 20 , F. Elsafy 7 , L. E. Fein 21 , A. Fielding9 , J. M. Ford22 , S. Friedman 23 , K. A. Gelmon24 , L. Gianni 25,26 , M. Gnant 27 , S. J. Hollingsworth 28 , S.-A. Im 29 , A. Jager30 , Ó. 3 Jóhannsson 31 , S. R. Lakhani 32 , W. Janni 33 , B. Linderholm 34,35 , T.-W. Liu 36 , N. Loman 37 , L. Korde38 , S. Loibl 39,40 , P. C. Lucas 1,41 , F. Marmé 42 , E. Martinez de Dueñas 43 , R. McConnell 8 , K.-A. Phillips 44,45 , M. Piccart 46 , G. Rossi47 , R. Schmutzler 48 , E. Senkus 49 , Z. Shao50 , P. Sharma 51 , C. F. Singer52 , T. Spanic53,54 , E. Stickeler 55 , M. Toi 56 , T. A. Traina 57 , G. Viale 58 , G. Zoppoli 59,60 , Y. H. Park61 , R. Yerushalmi 62,63 , H. Yang 64 , D. Pang65 , K. H. Jung 66 , A. Mailliez 67 , Z. Fan 68 , I. Tennevet 69 , J. Zhang 70 , T. Nagy 71 , G. S. Sonke72 , Q. Sun73 , M. Parton74 , M. A. Colleoni 75 , M. Schmidt 76 , A. M. Brufsky1,2 , W. Razaq 77 , B. Kaufman78y, D. Cameron79 , C. Campbell80 & A. N. J. Tutt81,82* , and the OlympiA Clinical Trial Steering Committee and Investigators
doi : 10.1016/j.annonc.2022.09.159
Volume 33, Issue 12, December 2022, Pages 1250-1268
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer
J. E. Berchuck 1 , F. Facchinetti2 , D. F. DiToro3 , I. Baiev4 , U. Majeed5 , S. Reyes 6 , C. Chen7 , K. Zhang8 , R. Sharman9 , P. L. S. Uson Junior 10 , J. Maurer 4 , R. T. Shroff 9 , C. C. Pritchard11 , M.-J. Wu 4 , D. V. T. Catenacci 12 , M. Javle 13 , L. Friboulet2 , A. Hollebecque 2 , N. Bardeesy 4 , A. X. Zhu14,15 , J. K. Lennerz3 , B. Tan 16 , M. Borad 17 , A. R. Parikh4 , L. A. Kiedrowski 18 , R. K. Kelley 8 , K. Mody 5 , D. Juric 4 & L. Goyal
doi : 10.1016/j.annonc.2022.09.150
Volume 33, Issue 12, December 2022, Pages 1269-1283
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas
P. Selenica 1y, A. Marra1y, N. J. Choudhury 2y, A. Gazzo1 , C. J. Falcon 3 , J. Patel1 , X. Pei1 , Y. Zhu1 , C. K. Y. Ng 4 , M. Curry 5 , G. Heller5 , Y.-K. Zhang6 , M. F. Berger1,7,8 , M. Ladanyi8 , C. M. Rudin 2,9 , S. Chandarlapaty 1,9 , C. M. Lovly 6 , J. S. Reis-Filho 1*z & H. A. Yu
doi : 10.1016/j.annonc.2022.09.151
Volume 33, Issue 12, December 2022, Pages 1284-1295
An international, open-label, randomised trial comparing a two-step approach versus the standard three-step approach of the WHO analgesic ladder in patients with cancer
M. Fallon1* , K. Dierberger 2 , M. Leng 3 , P. S. Hall 1,2 , S. Allende 4 , R. Sabar5 , E. Verastegui 4 , D. Gordon 1 , L. Grant6 , R. Lee 3 , K. McWillams 7 , G. D. Murray2 , L. Norris 1 , C. Reid8 , T. A. Sande1 , A. Caraceni9y, S. Kaasa 10,11y & B. J. A. Laird
doi : 10.1016/j.annonc.2022.08.083
Volume 33, Issue 12, December 2022, Pages 1296-1303
Leveraging big data of immune checkpoint blockade response identifies novel potential targets
Y. Bareche 1,2y, D. Kelly 3y, F. Abbas-Aghababazadeh4y, M. Nakano 4 , P. N. Esfahani 4 , D. Tkachuk4 , H. Mohammad 4 , R. Samstein5 , C.-H. Lee6 , L. G. T. Morris 7 , P. L. Bedard 3 , B. Haibe-Kains 4,8,9,10,11,12,13*z & J. Stagg
doi : 10.1016/j.annonc.2022.08.084
Volume 33, Issue 12, December 2022, Pages 1304-1317
Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes
C. Loveday1 , A. Garrett1 , P. Law 1 , S. Hanks 1 , E. Poyastro-Pearson1 , J. W. Adlard 2 , J. Barwell 3 , J. Berg4 , A. F. Brady5 , C. Brewer6 , C. Chapman7 , J. Cook 8 , R. Davidson 9 , A. Donaldson10 , F. Douglas 11 , L. Greenhalgh 12 , A. Henderson13 , L. Izatt14 , A. Kumar 15 , F. Lalloo16 , Z. Miedzybrodzka17 , P. J. Morrison18 , J. Paterson19 , M. Porteous 20 , M. T. Rogers21 , L. Walker 22 , The Breast and Ovarian Cancer Susceptibility Collaborationy, D. Eccles 23 , D.G. Evans16 , K. Snape 1,24 , H. Hanson 1,24 , R.S. Houlston 1 & C. Turnbull
doi : 10.1016/j.annonc.2022.09.152
Volume 33, Issue 12, December 2022, Pages 1318-1327
Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)
A. Bayle1,2,3,y, F. Peyraud 1,4,5,y, L. Belcaid 1,6 , M. Brunet 4 , M. Aldea 2,7 , R. Clodion 1 , P. Dubos 4 , D. Vasseur 8 , C. Nicotra1 , A. Geraud1 , M. Sakkal1 , L. Cerbone 7 , F. Blanc-Durand 7 , F. Mosele 7 , P. Martin Romano1 , M. Ngo Camus 1 , I. Soubeyran9 , E. Khalifa 9 , M. Alame 9 , L. Blouin 9 , D. Dinart 10,11 , C. Bellera 10,11 , A. Hollebecque 1 , S. Ponce1 , Y. Loriot1 , B. Besse 2,7 , L. Lacroix8 , E. Rouleau8 , F. Barlesi7,12 , F. Andre2,7 & A. Italiano
doi : 10.1016/j.annonc.2022.08.089
Volume 33, Issue 12, December 2022, Pages 1328-1331
Reply to the Letter to the Editor ‘Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification’ by Hannoun-Levi et al.
M. A. Franzoi 1 , D. Trapani 2,3 , S. Jezdic 4 , M. M. Regan 5 , G. Curigliano 6,7 * & F. Andre
doi : 10.1016/j.annonc.2022.09.154
Volume 33, Issue 12, December 2022, Pages 1331-1333
T cell receptor sequencing reveals reduced clonal breadth of T-cell responses against SARS-CoV-2 after natural infection and vaccination in allogeneic hematopoietic stem cell transplant recipients
A. Pradier 1,2,y, AC. Mamez 1,*y*, C. Stephan 1 , F. Giannotti 1 , S. Masouridi-Levrat1 , S. Wang 2 , S. Morin 1 , D. Neofytos 3 , D. L. Vu 3 , A. Melotti 2 , I. Arm 4 , C. S. Eberhardt 5 , J. Tamburini2 , L. Kaiser 3,4,6 , Y. Chalandon 1,2 & F. Simonetta
doi : 10.1016/j.annonc.2022.09.153
Volume 33, Issue 12, December 2022, Pages 1333-1335
